Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
The median bioavailabilities of aciclovir after administration of aciclovir and its prodrug valaciclovir were 21.5 and 70.1%, respectively, in 12 patients with malignant hematological diseases with leukopenia after chemotherapy. The interindividual variations of the bioavailability were 48.5 and 21.0% after administration of aciclovir and valaciclovir, respectively. Neither the bioavailability nor the interindividual variation of area under the concentration-time curve of oral aciclovir or valaciclovir differed from that reported in healthy volunteers.
Steingrimsdottir
H
H
Department of Medicine, Division of Hematology, Karolinska Hospital, SE-171 76 Stockholm, Sweden.
Gruber
A
A
Palm
C
C
Grimfors
G
G
Kalin
M
M
Eksborg
S
S
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D006801:Humans; D007970:Leukopenia / Q000188:drug therapy / Q000378:metabolism*; D011355:Prodrugs / Q000493:pharmacokinetics*; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D000998:Antiviral Agents; D011355:Prodrugs; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir